Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-exploration study of Visilizumab in intravenous steroid-refractory ulcerative colitis
2005-003482-17Phase 2Completed
- Sponsor
- PDL BioPharma
- Start
- Jan 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of visilizumab in autoimmune colitis (3 arms), sponsored by PDL BioPharma. Primary endpoint: Clinical response at Day 45. Started Jan 2006; status: completed.
02
Drugs
visilizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2005-003482-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003482-17.